Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diltiazem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S known ✓ | Q13698 | 11/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | PLAUR | Q03405 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diltiazem SCHEMBL3468378 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL17776 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127237 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL676914 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL614334 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL4886734 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL13575826 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127157 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL10831293 | 0.99 | CYP3A4 (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL8545465 | 0.99 | CYP3A4 (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4448506-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich Incorporated (US) | 2024-10-23 | — | — | EP | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| WO-2023172394-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | claimed |
| CN-113796309-B | Method for breeding maize inbred line parents by enhancing heterosis in different ecological regions | 鹤壁市农业科学院(浚县农业科学研究所) | 2022-10-21 | — | — | CN | claimed |
| US-20220079950-A1 | THERAPEUTIC COMBINATIONS AS ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE | UNIV CALIFORNIA (US) | 2022-03-17 | — | — | US | claimed |
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD (AU) | 2026-05-05 | — | — | US | disclosed |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | HALOZYME, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2026043960-A1 | CATASTROPHIC WILDFIRE INDEX FOR FORECASTING UTILITY-CAUSED WILDFIRES | Technosylva, Inc. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260034334-A1 | Pulmonary Embolism Apparatus | SANFORD HEALTH (US) | 2026-02-05 | — | — | US | disclosed |
| CN-114146057-A | Pharmaceutical composition and use thereof | 斯皮内特赫拉公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2022039478-A1 | METHOD FOR PREPARING DILTIAZEM SUSTAINED-RELEASE TABLET COMPOSITION BY USING SELF-GRANULATION | 한국휴텍스제약 주식회사 | 2022-02-24 | — | — | WO | disclosed |
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220023551-A1 | METHODS AND DEVICES FOR CONTROLLED DRUG VAPORIZATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113967212-A | Disproportionated rosin compound and preparation method and application thereof | 延边大学 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | CACNA1S 3106/4885CACNA1F 2980/4885CACNA1D 3475/4885 |
| US-20260034334-A1 | Pulmonary Embolism Apparatus | TOE1, PDE1C, NPR3 | CACNA1S 586/4885CACNA1F 1733/4885CACNA1D 940/4885 |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | PREP, HM13, MMP20 | CACNA1S 3157/4885CACNA1F 3868/4885CACNA1D 2624/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | CACNA1S 3800/4885CACNA1F 3480/4885CACNA1D 3698/4885 |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, IRF3 | CACNA1S 4035/4885CACNA1F 3556/4885CACNA1D 3434/4885 |
| US-20220079950-A1 | THERAPEUTIC COMBINATIONS AS ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE | SLC10A6, SLCO1B3, SLCO1B1 | CACNA1S 1827/4885CACNA1F 1954/4885CACNA1D 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.